Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
AstraZeneca
Covington
Novartis
Baxter
Mallinckrodt
Healthtrust
McKesson
QuintilesIMS
Boehringer Ingelheim

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,888,342

« Back to Dashboard

Which drugs does patent 7,888,342 protect, and when does it expire?

Patent 7,888,342 protects SAVELLA and is included in one NDA.

This patent has fourteen patent family members in nine countries.
Summary for Patent: 7,888,342
Title:Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
Abstract:The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s): Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (Encinitas, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Application Number:12/644,510
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 7,888,342

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 AB RX Yes No ➤ Subscribe ➤ Subscribe MANAGEMENT OF FIBROMYALGIA (FM) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,888,342

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,915,246 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Subscribe
6,602,911 Methods of treating fibromyalgia ➤ Subscribe
6,635,675 Method of treating chronic fatigue syndrome ➤ Subscribe
7,820,643 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Subscribe
6,992,110 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,888,342

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2322225 ➤ Subscribe
Spain 2433080 ➤ Subscribe
Mexico PA05000566 ➤ Subscribe
Canada 2467356 ➤ Subscribe
Spain 2395462 ➤ Subscribe
China 1671368 ➤ Subscribe
European Patent Office 1463528 ➤ Subscribe
European Patent Office 1545489 ➤ Subscribe
Portugal 1463528 ➤ Subscribe
Portugal 2322225 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Dow
Novartis
Federal Trade Commission
Julphar
Mallinckrodt
US Department of Justice
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot